Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy

Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy

Expression of N-glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivari...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of oncology 2020, Vol.2020 (2020), p.1-7
Hauptverfasser: Berk, Barkın, Yazar, Aziz, Dogan, Ender, Aydıncer, Cenk, Baloglu, Huseyin, Teomete, Mehmet, Ozkan, Metin, Mandel, Nil Molinas, Ayla, Sule, Uskent, Necdet, Yergok, Hale
Format: Artikel
Sprache:eng
Schlagworte:
Age
Analysis
Antibodies
Antigens
Cancer therapies
Gangliosides
Hypoxia
Immunotherapy
Lung cancer
Medical prognosis
Monoclonal antibodies
Mutation
Prognosis
Targeted cancer therapy
Tumors
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Expression of N-glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivariate analysis between overall survival and tissue NeuGcGM3 IHC levels. Although numerically there was a difference favoring less intense IHC for better prognosis, this did not reach statistical power. However, there was a strong correlation between Racotumomab doses and overall survival (OS). Mean OS of the patient with more than 10 Racotumomab application was significantly longer than the patient who had less than 10 injections (70.7 months vs. 31.1 months, p
ISSN:1687-8450
1687-8450
DOI:10.1155/2020/1360431